US10213393 — Composition and method for treating neurological disease
Method of Use · Assigned to Osmotica Kereskedelmi es Szolgaltato KFT · Expires 2038-02-15 · 12y remaining
What this patent protects
This patent protects a method of treating neurological disorders, such as Parkinson's disease, by administering a daily dose of 50-400 mg of extended-release amantadine.
USPTO Abstract
The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-20 |
Specific dosing regimen | amantadine-hydrochloride |
U-20 |
Specific dosing regimen | amantadine-hydrochloride |
U-20 |
Specific dosing regimen | amantadine-hydrochloride |
U-20 |
Specific dosing regimen | amantadine-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.